Towards individualized therapy for orphan cancer
- Prosjektnummer
- 2014047
- Ansvarlig person
- Ola Myklebost
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 5. Treatment Developement
NEI
NEI
Preclinical Evaluation of Vemurafenib as Therapy for BRAF
Int J Mol Sci 2018 Mar 23;19(4). Epub 2018 mar 23
PMID: 29570692
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.
Mol Cancer Ther 2018 Nov;17(11):2473-2480. Epub 2018 aug 10
PMID: 30097488
Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
Blood 2017 Nov 30. Epub 2017 nov 30
PMID: 29191918
Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b.
Sci Rep 2017 Aug 28;7(1):9655. Epub 2017 aug 28
PMID: 28848235
A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS.
Cell Rep 2017 Jul 11;20(2):411-426.
PMID: 28700942
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
Oncotarget 2016 Jan 05;7(1):433-45.
PMID: 26595521
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.
Oncotarget 2016 Aug 23;7(34):54583-54595.
PMID: 27409346
Monogenic and polygenic determinants of sarcoma risk: an international genetic study.
Lancet Oncol 2016 Sep;17(9):1261-71. Epub 2016 aug 4
PMID: 27498913
Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.
Oncotarget 2015 Feb 10;6(4):2451-65.
PMID: 25669981
Functional genomics analysis reveals a MYC signature associated with a poor clinical prognosis in liposarcomas.
Am J Pathol 2015 Mar;185(3):717-28. Epub 2015 jan 23
PMID: 25622542
The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.
Cancer Med 2014 Feb;3(1):36-46. Epub 2013 des 17
PMID: 24403055
Precision medicine for the treatment of a highly malignant and resistant type of liposarcoma
- Disputert:
- januar 2018
- Hovedveileder:
- Ola Myklebost
- Kirsten Sundby Hall Prosjektdeltaker
- Stine Næss Prosjektdeltaker
- Mahmood Aqsa Prosjektdeltaker
- Olga Zaikova Prosjektdeltaker
- Bodil Bjerkehagen Prosjektdeltaker
- Heidi Anine Korsmo Prosjektdeltaker
- Mona Mari Lindeberg Prosjektdeltaker
- Susanne Lorenz Prosjektdeltaker
- Leonardo Zepeda Meza Prosjektdeltaker
- Kjetil Boye Postdoktorstipendiat (annen finansiering)
- Else Munthe Postdoktorstipendiat (annen finansiering)
- Ola Myklebost Prosjektleder
- Eva Wessel Stratford Postdoktorstipendiat (finansiert av denne bevilgning)
- David Thomas Prosjektdeltaker
- Synnøve Granlien Prosjektdeltaker
- Øyvind Bruland Prosjektdeltaker
- Robert Hanes Doktorgradsstipendiat (annen finansiering)
- Hildegunn Høberg Vetti Prosjektdeltaker
- Jan Helge Solbakk Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport